Molecular Adsorbent Recirculating System (MARS) in Patients with Primary Nonfunction and Other Causes of Graft Dysfunction After Liver Transplantation in the Era of Extended Criteria Donor Organs

Transplantation Proceedings

Volumn 41, Issue 1, 2009, Pages 253-258

  Gaspari, R ^a   Cavaliere, F ^a   Sollazzi, L ^a   Perilli, V ^a   Melchionda, I ^a   Agnes, S ^a   Gasbarrini, A ^a   Avolio, A W ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; BILE ACID; BILIRUBIN; CREATININE;

ADULT; ALBUMIN DIALYSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; DIALYSIS; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PATIENT SAFETY; PRIORITY JOURNAL; PRURITUS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; BUDD-CHIARI SYNDROME; CARCINOMA, HEPATOCELLULAR; HEMOCHROMATOSIS; HUMANS; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MIDDLE AGED; PATIENT SELECTION; RENAL DIALYSIS; REOPERATION; SORPTION DETOXIFICATION; TISSUE DONORS; TREATMENT FAILURE;

EID: 60649091130     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.066     Document Type: Article

References (27)

1. Ploeg R.J., D'Alessandro A.M., Knechtle S.J., et al. Risk factor for primary dysfunction after liver transplantation: a multivariate analysis. Transplantation 55 (1993) 807
2. Deschênes M., Belle S.H., Krom R.A., et al. Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation 66 (1998) 302
3. Stange J., Ramlow W., Mitzner S., et al. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 17 (1993) 809
4. Stange J., Mitzner S.R., Risler T., et al. Molecular adsorbents recycling system (MARS): clinical result of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 23 (1999) 319
5. Heemann U., Treichel U., Loock J., et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36 (2002) 949
6. Novelli G., Rossi M., Pretagostini R., et al. One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 37 (2005) 2557
7. Koivusalo A.M., Vakkuri A., Höckerstedt K., et al. Experience of MARS therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc 37 (2005) 3315
8. Camus C., Lavoué S., Gacouin A., et al. Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 32 (2006) 1817
9. Gaspari R., Avolio A.W., Zileri Dal Verme L., et al. Molecular adsorbent recirculating system in liver transplantation: safety and efficacy. Transplant Proc 38 (2006) 3544
10. Chiu A., Chan L.M., and Fan S.T. Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Liver Int 26 (2006) 695
11. Tector A.J., Mangus R.S., Chestovich P., et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg 244 (2006) 439
12. Renz J.F., Kin C., Kinkhabwala M., et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg 242 (2005) 556
13. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparision of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72 (1977) 573
14. Müller C., Pongratz S., Pidlich J., et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 10 (1998) 865
15. Briceno J., Padillo J., Rufián S., et al. Assignment of steatotic liver by the Mayo model for end stage liver disease. Transpl Int 18 (2005) 577
16. Demetriou A.A., Brown R.S., Busuttil R.W., et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 239 (2004) 660
17. Hassanein T.I., Tofteng F., Brown Jr. R.S., et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46 (2007) 1853
18. Loock J., Treichel U., Gerken G., et al. Treatment of split-liver recipients with poor graft function by albumin-dialysis (Mars). Z Gastroenterol 39 2 (2001) 18
19. Jost U., Schreiter D., Sceibner L., et al. Continuos venovenous hemofiltration with extracorporeal albumin dialysis "MARS" in critically ill patients before and after liver transplantation. Z Gastroenterol 39 2 (2001) 43
20. Kasakow L., Hommannn M., Wagner T.H., et al. Application of artificial liver support (MARS) after split-liver transplantation in an infant. Z Gastroenterol 39 2 (2001) 50
21. Delafosse B., Garnier E., Durmortier J., et al. Experience with the MARS in 5 patients experiencing hepatic failure. Z Gastroenterol 39 2 (2001) 50
22. Kellersmann R., Gassel H.J., Bühler C., et al. Application of molecular adsorbent recirculating system in patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences. Liver 22 2 (2002) 56
23. Bellmann R., Graziadei I.W., Feistritzer C., et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 10 (2004) 107
24. Montero J.L., Pozo J.C., Barrera P., et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 38 (2006) 2511
25. Hetz H., Faybik P., Berlakovich G., et al. Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: a pilot study. Liver Transpl 12 (2006) 1357
26. Scheingraber S., Richter S., Igna D., et al. Indocynine green elimination but not bilirubin indicates improvement of graft function during MARS therapy. Clin Transplant 21 (2007) 689
27. Azoulay D., Linhares M.M., Huguet E., et al. Decision for retransplantation of the liver: an experience-and cost-based analysis. Ann Surg 236 (2002) 713